Coartem Artemether Lumefantrine Tablet
Coartem (Artemether + Lumefantrine) Tablet WHO First-Line ACT for Uncomplicated Malaria Narix Pharmaceuticals
Narix Pharmaceuticals manufactures Artemether + Lumefantrine FDC Tablets, the WHO first-line Artemisinin Combination Therapy (ACT) for uncomplicated Plasmodium falciparum malaria � providing rapid parasite clearance (artemether) with sustained elimination (lumefantrine).
Key Therapeutic Uses:
� Uncomplicated Plasmodium falciparum malaria � WHO first-line
� Multi-drug resistant falciparum malaria
� Mixed Plasmodium infections
Available Strengths: Artemether 20 mg + Lumefantrine 120 mg (pediatric and adult)
Product Highlights:
� WHO first-line ACT � global malaria treatment standard
� WHO essential medicine � EML listed
� 3-day 6-dose regimen � high compliance
� WHO-GMP, DCGI approved
� High export to Africa, ASEAN malaria-endemic regions
� PCD pharma franchise & bulk export
Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M
#ArtemetheLumefantrineTablet #CoartemGeneric #LumeraxGeneric #ACTMalarial #FalciparumMalaria #ArtemisinCombinationTherapy #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine